TY - JOUR
T1 - Level I PD-MCI Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia
AU - MDS Study Group Mild Cognitive Impairment in Parkinson's Disease
AU - Boel, Judith A.
AU - de Bie, Rob M.A.
AU - Schmand, Ben A.
AU - Dalrymple-Alford, John C.
AU - Marras, Connie
AU - Adler, Charles H.
AU - Goldman, Jennifer G.
AU - Tröster, Alexander I.
AU - Burn, David J.
AU - Litvan, Irene
AU - Geurtsen, Gert J.
AU - Bernard, Bryan
AU - Stebbins, Glenn
AU - Filoteo, J. Vincent
AU - Weintraub, Daniel
AU - Caviness, John N.
AU - Belden, Christine
AU - Zabetian, Cyrus P.
AU - Cholerton, Brenna A.
AU - Huang, Xuemei
AU - Eslinger, Paul J.
AU - Leverenz, James B.
AU - Duff-Canning, Sarah
AU - Farrer, Matt
AU - Anderson, Tim J.
AU - Myall, Daniel J.
AU - Naismith, Sharon L.
AU - Lewis, Simon J.G.
AU - Halliday, Glenda M.
AU - Wu, Ruey Meei
AU - Williams-Gray, Caroline H.
AU - Breen, David P.
AU - Barker, Roger A.
AU - Yarnall, Alison J.
AU - Klein, Martin
AU - Mollenhauer, Brit
AU - Trenkwalder, Claudia
AU - Kulisevsky, Jaime
AU - Pagonabarraga, Javier
AU - Gasca-Salas, Carmen
AU - Rodriguez-Oroz, Maria C.
AU - Junque, Carme
AU - Segura, Barbara
AU - Barone, Paolo
AU - Santangelo, Gabriella
AU - Cammisuli, Davide M.
AU - Biundo, Roberta
AU - Antonini, Angelo
AU - Weis, Luca
AU - Pedersen, Kenn Freddy
AU - Schmand, Bernardus A.
N1 - Funding Information: Judith A. Boel, Rob M.A. de Bie, Ben A. Schmand, Jennifer G. Goldman, Alexander I. Tröster, David J. Burn, and Gert J. Geurtsen have no disclosures to report. John C. Dalrymple‐Alford, None, only grants from Tertiary Education Commission, New Zealand, Health Research Council of New Zealand, Canterbury Medical Research Foundation and Neurological Foundation of New Zealand. Connie Marras is a consultant for Gray Matter Technologies and receives financial compensation as a steering committee member from the Michael J Fox Foundation. She received grants from The Michael J Fox Foundation, Canadian Institutes of Health Research, Parkinson's Foundation (US), International Parkinson and Movement Disorders Society, Weston Brain Institute, Theravance Inc, Centogene. Charles H. Adler has Stock Ownership in medically‐related fields: Cionic; Consultancies: Avion, CND Life Science, Jazz Pharm, Neurocrine; Grants: NIH, Michael J. Fox Foundation, Arizona Biomedical Research Commission. Irene Litvan's research is supported by the National Institutes of Health grants: 2R01AG038791‐06A, U01NS100610, U01NS80818, R25NS098999; U19 AG063911‐1 and 1R21NS114764‐01A1; the Michael J Fox Foundation, Parkinson Foundation, Lewy Body Association, CurePSP, Roche, Abbvie, Biogen, Centogene. EIP‐Pharma, Biohaven Pharmaceuticals, Novartis, Brain Neurotherapy Bio and United Biopharma SRL—UCB. She was a member of the Scientific Advisory Board of Lundbeck and is a Scientific advisor for Amydis. She receives her salary from the University of California San Diego and as Chief Editor of . Financial Disclosures for the Previous 12 Months: Frontiers in Neurology Publisher Copyright: © 2022 AmsterdamUMC. Movement Disorders Clinical Practice published by Wiley Periodicals LLC on behalf of Movement Disorder Society.
PY - 2022/5
Y1 - 2022/5
N2 - Background: The criteria for PD-MCI allow the use of global cognitive tests. Their predictive value for conversion from PD-MCI to PDD, especially compared to comprehensive neuropsychological assessment, is unknown. Methods: The MDS PD-MCI Study Group combined four datasets containing global cognitive tests as well as a comprehensive neuropsychological assessment to define PD-MCI (n = 467). Risk for developing PDD was examined using a Cox model. Global cognitive tests were compared to neuropsychological test batteries (Level I&II) in determining risk for PDD. Results: PD-MCI based on a global cognitive test (MMSE or MoCA) increases the hazard for developing PDD (respectively HR = 2.57, P = 0.001; HR = 4.14, P = <0.001). The C-statistics for MMSE (0.72) and MoCA (0.70) were lower than those based on neuropsychological tests (Level I = 0.82; Level II = 0.81). Sensitivity, specificity and diagnostic accuracy balance was best in Level II. Conclusion: MMSE and MoCA predict conversion to PDD. However, Level II neuropsychological assessment seems the preferred assessment for PD-MCI.
AB - Background: The criteria for PD-MCI allow the use of global cognitive tests. Their predictive value for conversion from PD-MCI to PDD, especially compared to comprehensive neuropsychological assessment, is unknown. Methods: The MDS PD-MCI Study Group combined four datasets containing global cognitive tests as well as a comprehensive neuropsychological assessment to define PD-MCI (n = 467). Risk for developing PDD was examined using a Cox model. Global cognitive tests were compared to neuropsychological test batteries (Level I&II) in determining risk for PDD. Results: PD-MCI based on a global cognitive test (MMSE or MoCA) increases the hazard for developing PDD (respectively HR = 2.57, P = 0.001; HR = 4.14, P = <0.001). The C-statistics for MMSE (0.72) and MoCA (0.70) were lower than those based on neuropsychological tests (Level I = 0.82; Level II = 0.81). Sensitivity, specificity and diagnostic accuracy balance was best in Level II. Conclusion: MMSE and MoCA predict conversion to PDD. However, Level II neuropsychological assessment seems the preferred assessment for PD-MCI.
KW - Parkinson's disease
KW - dementia
KW - diagnostic accuracy
KW - global cognitive tests
KW - mild cognitive impairment
UR - http://www.scopus.com/inward/record.url?scp=85131576601&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/mdc3.13451
DO - https://doi.org/10.1002/mdc3.13451
M3 - Article
C2 - 35582313
SN - 2330-1619
VL - 9
SP - 479
EP - 483
JO - Movement Disorders Clinical Practice
JF - Movement Disorders Clinical Practice
IS - 4
ER -